Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing
Journal of Antimicrobial Chemotherapy · 01.03.2024 · 79 (3) · 685-687
DOI: 10.1093/jac/dkad407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.12.2023. Verfasst von Manon Deschamps und 2 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR 1184, University Paris-Saclay, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Aztreonam, Anti-Bacterial Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The emergence of carbapenemase-producing Gram-negative bacteria (GNB) raises new issues in terms of therapeutic management, with increasing resistance to available antibiotics. MBL-producing GNB are particularly problematic, as the only β-lactam active against this type of carbapenemase is aztreonam.1,2 In addition, MBL producers often co-express other ESBLs or cephalosporinases that hydrolyse aztreonam. Consequently, it has been demonstrated that the combination of aztreonam + ceftazidime/avibactam can be an effective therapeutic alternative in the treatment of infections caused by MBL producers.1–3 Indeed, avibactam inhibits the aztreonam-hydrolysing β-lactamases and restores the susceptibility of the MBL producers to aztreonam. The use of aztreonam/avibactam or cefiderocol is now considered as the reference for the treatment of infections caused by MBL-producing GNB according to ESCMID4 and IDSA.5 In this context, it is crucial to accurately determine the susceptibility of aztreonam/avibactam. Until now, the determination of aztreonam/avibactam MIC in routine relied on a successive overlaying of two ETEST® strips (ceftazidime/avibactam then aztreonam) (bioMérieux).3 Recently, a diffusion gradient MTS™ Aztreonam-avibactam strip (Liofilchem) has been launched. Here, were compare the ETEST® strip overlaying method and the MTS™ Aztreonam-avibactam strip to the aztreonam/avibactam broth microdilution method (considered as reference but not commercially available) for the determination of aztreonam/avibactam MIC. We used a collection of 145 clinical isolates that produce at least one MBL and were resistant to aztreonam. These strains from the University Hospital of Lyon and the French National Reference Center for Antibiotic Resistance (122 Enterobacterales, 6 Acinetobacter baumannii, 13 Pseudomonas aeruginosa and 4 Stenotrophomonas maltophilia), included 123 carbapenemase producers (72 NDM, 29 VIM, 20 NDM + OXA-48-like, 1 VIM + OXA-48-like, 1 VIM + NDM) (Table S1, available as Supplementary data at JAC Online). WGS was performed on all isolates to assess resistance genes. Broth microdilution was performed (Sensititre, Thermo Fisher) using a fixed concentration of 4 mg/L avibactam. As previously described,3 the sequential superimposition of two ETEST® (bioMérieux) strips (ceftazidime/avibactam then aztreonam) on Mueller–Hinton agar (Bio-Rad). The MTS™ Aztreonam-avibactam (Liofilchem) diffusion gradient strip was performed on Mueller–Hinton agar (Bio-Rad), as recommended by the manufacturer. All susceptibility testing methods (broth microdilution ETEST® overlaying method and MTS™ Aztreonam-avibactam strip) were performed using the same 0.5 Mc Farland inoculum used for the reference broth microdilution on Mueller–Hinton agar (Bio-Rad). EUCAST aztreonam breakpoints as updated in 2023 (www.eucast.org) were used for both aztreonam and aztreonam/avibactam categorization: susceptible for MIC ≤ 1 mg/L, high-exposure susceptible for 1 mg/L 4 mg/L. Essential agreement (EA) (% of isolate with MIC within one 2-fold dilution compared with the reference method) and bias (aim to identify any tendency of over- or down-estimation of the MIC and calculated as follows: % of isolates with MIC ≥ one 2-fold dilution compared with the reference method − % of isolates with MIC ≤ one 2-fold dilution compared with the reference method) were calculated to evaluate the performances of the ETEST® overlaying method and the MTS™ Aztreonam-avibactam strip as recommended in the ISO 20776-2:2021 document, using broth microdilution as reference. Congruent expected performances were: EA ≥ 90%, −30% ≤ bias ≤ + 30%. Rates of categorical agreement (CA), major errors (MEs) and very major errors (VMEs) were also calculated following the definition from ISO 20776-2:2007. According to the reference method, MICs of aztreonam/avibactam ranged from ≤0.03 to >64 mg/L, with 76.6% (n = 111/145) being susceptible isolates (MIC ≤ 1 mg/L), 9.7% (n = 14/145) of strains categorized as susceptible upon high exposure (1 mg/L 4 mg/L) (Figure 1). Compared with the reference method, the ETEST® overlay displayed EA of 77.2% (95% CI = 70.4–84.1), bias of 20.7%, CA of 76.6% (95% CI = 69.7–83.4), 0% VMEs, 1.4% MEs and 22.1% minor errors (mEs). The MTS™ Aztreonam-avibactam displayed EA of 91.7% (95% CI = 87.2–96.2), bias of 14.5%, CA of 89.7% (95% CI = 84.7–94.6), 0% VMEs, 0% MEs and 10.3% mEs (Figure 1). Correlation between MICs of aztreonam/avibactam obtained using (a) ceftazidime/avibactam and aztreonam ETEST® superposition method and (b) MTS™ Aztreonam-avibactam strip compared with the reference broth microdilution method on 145 Enterobacterales, A. baumannii, P. aeruginosa and S. maltophilia. EA is indicated in green, mEs in orange, MEs (false resistant) in blue and VMEs (false susceptible) in red. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. In conclusion, the ETEST® strip overlay did not meet the expected performances (EA < 90% with a 95% CI below 90%) for the determination of aztreonam/avibactam MIC but VMEs have not been observed, confirming the safe use of this method in routine.3 One of the issues raised in the literature regarding the use of ETEST® strip overlay is its technical complexity (depositing one strip for a defined period of time, followed by removal and insertion of the second strip), which is responsible for greater variability in the results.6 The new MTS™ Aztreonam/avibactam strips appeared to be an easy-to-use option with a high concordance with the reference method and can be easily used on a routine basis. The MEs and mEs mostly related to the fact that the ETEST® strip overlay and MTS™ Aztreonam-avibactam strip possess intermediate graduations while the reference method can determine MICs with 2-fold dilution values. This study was supported by internal funding. None to declare. Table S1 is available as Supplementary data at JAC Online.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- INSERM UMR 1184, University Paris-Saclay, Le Kremlin-Bicêtre, France.
- Depatment of Bacteriology-hygiene, Bicêtre hospital, Assistance Publique des Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
- Northern Biology and Pathology Centre, Hospices Civiles of Lyon, Lyon, France.
- French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France.
ORCID-Profile: Laurent Dortet
Zitieren
APA
Deschamps, M., Dauwalder, O., & Dortet, L. (2024). Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing. Journal of Antimicrobial Chemotherapy, 79(3), 685-687. https://doi.org/10.1093/jac/dkad407
Vancouver
Deschamps M, Dauwalder O, Dortet L. Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing. Journal of Antimicrobial Chemotherapy. 2024;79(3):685-687. doi:10.1093/jac/dkad407
BibTeX
@article{Deschamps2024,
author = {Deschamps, Manon and Dauwalder, Ollivier and Dortet, Laurent},
title = {Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {3},
pages = {685--687},
doi = {10.1093/jac/dkad407}
}
EUVIMED